1.11
price down icon1.77%   -0.02
after-market Handel nachbörslich: 1.13 0.02 +1.80%
loading
Schlusskurs vom Vortag:
$1.13
Offen:
$1.14
24-Stunden-Volumen:
46,795
Relative Volume:
0.22
Marktkapitalisierung:
$33.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-60.70M
KGV:
-0.5441
EPS:
-2.04
Netto-Cashflow:
$-61.05M
1W Leistung:
+5.71%
1M Leistung:
+0.91%
6M Leistung:
-11.90%
1J Leistung:
-61.86%
1-Tages-Spanne:
Value
$1.11
$1.145
1-Wochen-Bereich:
Value
$1.06
$1.15
52-Wochen-Spanne:
Value
$0.87
$2.95

An 2 Therapeutics Inc Stock (ANTX) Company Profile

Name
Firmenname
An 2 Therapeutics Inc
Name
Telefon
(650) 331-9090
Name
Adresse
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Name
Mitarbeiter
36
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
ANTX's Discussions on Twitter

Vergleichen Sie ANTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ANTX
An 2 Therapeutics Inc
1.11 31.68M 0 -60.70M -61.05M -2.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-09 Herabstufung Evercore ISI In-line → Underperform
2024-08-09 Herabstufung Leerink Partners Outperform → Market Perform
2024-07-03 Hochstufung Leerink Partners Market Perform → Outperform
2024-04-02 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2024-02-13 Herabstufung Leerink Partners Outperform → Market Perform
2024-02-12 Herabstufung Evercore ISI Outperform → In-line
2024-02-12 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2024-02-12 Herabstufung Oppenheimer Outperform → Perform
2024-01-04 Eingeleitet JMP Securities Mkt Outperform
2022-07-18 Fortgesetzt Oppenheimer Outperform
Alle ansehen

An 2 Therapeutics Inc Aktie (ANTX) Neueste Nachrichten

pulisher
Jul 16, 2025

Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC - GlobeNewswire

Jul 16, 2025
pulisher
Jul 15, 2025

Ovid Therapeutics (NASDAQ:OVID) Stock Price Down 2% – Time to Sell? - Defense World

Jul 15, 2025
pulisher
Jul 10, 2025

Cognition Therapeutics, Inc. Discusses Phase 2 Results and Future Plans for Zervimesine Treatment in Alzheimer's Disease with FDA - Nasdaq

Jul 10, 2025
pulisher
Jul 10, 2025

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease - GlobeNewswire

Jul 10, 2025
pulisher
Jul 10, 2025

Breakthrough for Alzheimer's Treatment: FDA Meeting Clears Path for Zervimesine Phase 3 Program - Stock Titan

Jul 10, 2025
pulisher
Jul 08, 2025

Unicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher – Time to Buy? - Defense World

Jul 08, 2025
pulisher
Jul 07, 2025

Apogee Therapeutics Announces Positive 16-Week Data from - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

New Atopic Dermatitis Drug Shows Record-Breaking 67% Success Rate, Could Reduce Injections to Just 4 Times Per Year - Stock Titan

Jul 07, 2025
pulisher
Jul 07, 2025

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) - Yahoo Finance

Jul 07, 2025
pulisher
Jul 03, 2025

Alembic Pharmaceuticals up 2% as arm acquires Utility Therapeutics; details - Business Standard

Jul 03, 2025
pulisher
Jul 01, 2025

Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat - Insider Monkey

Jul 01, 2025
pulisher
Jun 30, 2025

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program - Yahoo Finance

Jun 30, 2025
pulisher
Jun 27, 2025

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer - GlobeNewswire

Jun 27, 2025
pulisher
Jun 25, 2025

Perfuse Therapeutics shares positive results from Phase 2 clinical trials of PER-001 - Ophthalmology Times

Jun 25, 2025
pulisher
Jun 24, 2025

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business Wire

Jun 24, 2025
pulisher
Jun 23, 2025

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency - Yahoo Finance

Jun 23, 2025
pulisher
Jun 20, 2025

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO - GlobeNewswire

Jun 20, 2025
pulisher
Jun 17, 2025

$452M Deal: Processa's Phase 2 Gastroparesis Drug Shows Promise, Attracts Major Licensing Interest - Stock Titan

Jun 17, 2025
pulisher
Jun 14, 2025

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire

Jun 14, 2025
pulisher
Jun 13, 2025

Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress - GlobeNewswire

Jun 13, 2025
pulisher
Jun 12, 2025

Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025 - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance

Jun 12, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics, Inc. Announces Pricing of Public Offering - PR Newswire

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - PR Newswire

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study - Morningstar

Jun 11, 2025
pulisher
Jun 05, 2025

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-023, a Potential Best-in-Class, Novel CDK4 Selective Inhibitor - Business Wire

Jun 05, 2025
pulisher
Jun 03, 2025

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate - Business Wire

Jun 03, 2025
pulisher
Jun 02, 2025

Aclaris Therapeutics, Inc. Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210 - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Allarity Therapeutics Announces First Patient Enrolled in - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - PR Newswire

Jun 02, 2025
pulisher
Jun 02, 2025

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Actuate Therapeutics Shares Highlights from KOL Event on - GlobeNewswire

Jun 02, 2025
pulisher
Jun 01, 2025

Certain Stock Options of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - The Malaysian Reserve

Jun 01, 2025
pulisher
May 31, 2025

Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025 - Insider Monkey

May 31, 2025
pulisher
May 31, 2025

Xilio Therapeutics Announces Updated Phase 2 Data for - GlobeNewswire

May 31, 2025
pulisher
May 31, 2025

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - Yahoo Finance

May 31, 2025
pulisher
May 29, 2025

Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

May 29, 2025
pulisher
May 28, 2025

Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS - PR Newswire

May 28, 2025
pulisher
May 27, 2025

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - Business Wire

May 27, 2025
pulisher
May 27, 2025

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire

May 27, 2025
pulisher
May 23, 2025

Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail

May 23, 2025
pulisher
May 22, 2025

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - Yahoo Finance

May 22, 2025
pulisher
May 21, 2025

Tango Therapeutics, Inc. Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients with MTAP-Deleted Glioblastoma and Other Solid Tumors - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Tango Therapeutics Announces First Patient Dosed in TNG456 - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors - Yahoo Finance

May 21, 2025

Finanzdaten der An 2 Therapeutics Inc-Aktie (ANTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):